The earlier, the better

Hypertension Research

Volumn 30, Issue 1, 2007, Pages 1-2

  Kiyomoto, Hideyasu ^a   Hitomi, Hirofumi ^a  

^a KAGAWA UNIVERSITY   (Japan)

Author keywords

Angiotensin II receptor blockers (ARB); L NAME; Nitric oxide; Oxidative stress; TROPHY study

Indexed keywords

ALDOSTERONE; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CALCIUM ANTAGONIST; CANDESARTAN; DELAPRIL; N(G) NITROARGININE METHYL ESTER; PLACEBO; VASODILATOR AGENT;

BLOOD PRESSURE REGULATION; CLINICAL TRIAL; DIABETIC NEPHROPATHY; DISEASE COURSE; DRUG EFFICACY; EARLY INTERVENTION; EDITORIAL; ENDOCRINE FUNCTION; HUMAN; HYPERTENSION; KIDNEY DISEASE; KIDNEY FUNCTION; NEPHROSCLEROSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RENOVASCULAR HYPERTENSION;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BLOOD PRESSURE; DISEASE PROGRESSION; HUMANS; HYPERTENSION; KIDNEY DISEASES; RENIN-ANGIOTENSIN SYSTEM; TIME FACTORS;

EID: 33847032062     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1291/hypres.30.1     Document Type: Editorial

References (12)

1. Ikeda N, Hasegawa T, Hasegawa T, Saito I, Saruta T: Awareness of the Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2000) and compliance to its recommendations: surveys in 2000 and 2004. J Hum Hypertens 2006; 20: 263-266.
2. Nagai Y, Yao L, Kobori H, et al: Temporary angiotensin II blockade at the prediabetic stage attenuates the development of renal injury in type 2 diabetic rats. J Am Soc Nephrol 2005; 16: 703-711.
3. Hilgers KF, Veelken R: Type 2 diabetic nephropathy: never too early to treat? J Am Soc Nephrol 2005; 16: 574-575.
4. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-2997.
5. Dahlof B, Devereux RB, Kjeldsen SE, et al, LIFE Study Group: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003.
6. Pfeffer MA, Swedberg K, Granger CB, et al, CHARM Investigators and Committees: Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003; 362: 759-766.
7. Julius S, Nesbitt SD, Egan BM, et al, Trial of Preventing Hypertension (TROPHY) Study Investigators: Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med 2006; 354: 1685-1697.
8. Nakaya H, Sasamura H, Hayashi M, Saruta T: Temporary treatment of prepubescent rats with angiotensin inhibitors suppresses the development of hypertensive nephrosclerosis. J Am Soc Nephrol 2001; 12: 659-666.
9. Nakaya H, Sasamura H, Kitamura Y, et al: Effects of angiotensin inhibitors on renal injury and angiotensin receptor expression in early hypertensive nephrosclerosis. Hypertens Res 1999; 22: 303-312.
10. Ishiguro K, Sasanuma H, Sakamaki Y, Itoh H, Saruta T: Developmental activity of the renin-angiotensin system during the "critical period" modulates later L-NAME-induced hypertension and renal injury. Hypertens Res 2007; 30: 63-75.
11. Airoldi F, Palatresi S, Marana I, et al: Angioplasty of atherosclerotic and fibromuscular renal artery stenosis: time course and predicting factors of the effects on renal function. Am J Hypertens 2000; 13: 1210-1217.
12. Ramos F, Kotliar C, Alvarez D, et al: Renal function and outcome of PTRA and stenting for atherosclerotic renal artery stenosis. Kidney Int 2003; 63: 276-282.